A+ Science was established in 1997 as a subsidiary to Gothenburg University. The story began when Björn Dahlöf, Peter Held, Åke Hjalmarsson, Olle Isaksson and Karl Swedberg, all dedicated researchers within the cardiovascular field, formed A+ Science. The liaison to the academic world distinguished A+ Science from many other CROs.

The forming of the company was the result of a clinical trial idea, designed and further developed by Björn Dahlöf. The study was named ASCOT and 20 000 patients from five countries were randomized. Publications in The Lancet in 2003 and 2005 led to changes in the guiding principles and in the treatment of cardiovascular diseases. It gradually became a full service CRO in the region treatment of cardiovascular diseases.

The selection of services expanded as the number of customers increased. Even medical device studies were successfully completed.
The Stockholm office opened on 1st of January 2001, where many of the company’s customers were located. By now the company proved experience within several therapy areas and from studies in both early and late phases. Since the establishment of the company, A+ Science has collaborated with several of the world’s largest pharmaceutical companies and been involved in many hundreds of clinical trials.

Besides conducting clinical trials, A+ Science is also involved in organizing accredited Continuing Medical Education (CME) activities in collaboration with the Sahlgrenska Academy, University of Gothenburg and University Hospital of Umeå (UHU). Accredited CME events help healthcare professionals maintain and assure high level of theoretic and clinical competence. It is an opportunity to improve one’s professional performance and present the results of new clinical research to ensure better and safer treatments for patients.

Since December 2013, A+ Science is a CRO run by its employees. The majority of the company's ownership is among the company's employees.